ReviewInternational archives of allergy and immunology2026
Pollen-Food Allergy Syndrome in China: Current Knowledge and Future Research Needs.
Review in International archives of allergy and immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in Food Processing Techniques for Allergenicity Reduction and Allergen Identification.Foods (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
<p>Background: Pollen-food allergy syndrome (PFAS) is a distinct form of IgE-mediated food allergy that occurs in individuals sensitized to pollen. The characteristics of PFAS vary across regions and exhibit significant heterogeneity due to differing pollen sensitization profiles. Summary: Research on PFAS in China has primarily focused on Northern regions, where weed and tree pollen allergy, particularly to Artemisia, are prevalent. PFAS is more commonly observed in China among patients allergic to Artemisia pollen, nsLTPs (e.g., Art v 3) derived from Artemisia pollen is regarded as a biomarker for severe food-pollen allergies in China. Other cross-reactive components, including PR-10, profilins, and recently identified GRP, also contribute to PFAS. Diagnosis mainly relies on clinical history, supported by specific IgE, skin prick testing, and component-resolved diagnostics (CRD), while management includes dietary modifications, allergen avoidance, and epinephrine for anaphylaxis. Although allergen immunotherapy and biologics have been explored, their efficacy remains limited, highlighting unmet needs for further research. Critical knowledge gaps persist in understanding PFAS epidemiology, risk factors, and regional variations in China. Future priorities include large-scale epidemiological studies, validation of diagnostic tools, and the development of tailored management guidelines for China's diverse population. Key Messages: This review aimed to provide a comprehensive overview of PFAS and its management to enhance understanding of the existing knowledge gaps and future research needs in China. </p>.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.